What it's for (Indications)
- Tetrachlorodecaoxide (Oxoferin) is indicated for the topical treatment of various chronic and acute wounds where local oxygenation, antimicrobial activity, and promotion of tissue regeneration are beneficial.
- This includes, but is not limited to, chronic non-healing wounds such as pressure ulcers (bedsores), diabetic foot ulcers, and venous stasis ulcers, which often suffer from hypoxia and persistent infection.
- It is also used in the management of radiation-induced tissue damage, including radiation mucositis, radiation proctitis, and radiation dermatitis, where it may alleviate symptoms and promote healing.
- Furthermore, it can be applied to superficial and partial-thickness burns, promoting epithelialization and reducing bioburden.
- Its application aims to create an optimal wound healing environment by fostering granulation tissue formation, supporting epithelialization, and potentially reducing local infection, thus preparing the wound bed for repair and closure.
- The therapeutic scope is generally limited to topical applications that benefit from oxidative burst and local oxygenation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Tetrachlorodecaoxide is typically administered as a topical solution, gel, or cream, with specific concentrations varying (e.g., 0.1% or 0.2% TCDO). The exact dosage regimen and formulation depend on the specific medical condition, wound type, and patient response. Generally, it is applied directly to the affected area or impregnated onto a suitable dressing, typically once to three times daily, or as prescribed by a healthcare professional. Before application, the wound area should be meticulously cleaned and debrided according to standard wound care protocols to remove necrotic tissue and exudate, ensuring direct contact of the medication with the wound bed. The duration of treatment should be determined by ongoing clinical assessment of wound healing progress and should not exceed the period deemed necessary by the treating physician. Patients and caregivers should always follow the manufacturer's instructions and the prescribing clinician's guidance for optimal and safe use to achieve the best therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Local adverse reactions are the most commonly reported side effects associated with topical tetrachlorodecaoxide application.
- These may include transient sensations of burning, stinging, itching (pruritus), erythema (redness), or localized pain at the application site, particularly upon initial application or in highly sensitive wounds.
- These symptoms are generally mild to moderate in intensity and tend to resolve with continued use as the wound healing progresses or upon discontinuation of the product.
- Allergic contact dermatitis, although rare, can occur and may manifest as increased redness, swelling, blistering, or severe itching beyond the expected local irritation; immediate discontinuation is warranted in such cases, and medical advice should be sought.
- Temporary discoloration of the skin or wound bed, often appearing as a yellowish or brownish tint, may also be observed due to the oxidative properties of the compound, but this is usually benign and reversible.
- Systemic side effects are highly improbable given the negligible absorption of the compound through intact or compromised skin, making it generally well-tolerated when used as directed.
Serious Warnings
- Black Box Warning: As of current medical literature and regulatory information, tetrachlorodecaoxide (Oxoferin) does not carry an FDA-mandated Black Box Warning. Given its topical route of administration and limited systemic absorption, it is generally considered to have a favorable safety profile for its indicated uses. However, clinicians and patients should be aware of **Serious Warnings**: This product is strictly for external topical use. Ingestion is not indicated and can be harmful. Avoid contact with eyes; if accidental exposure occurs, irrigate thoroughly with water and seek immediate medical attention. Discontinue use if severe local irritation, pain, blistering, or signs of allergic reaction (e.g., increased erythema, swelling, pruritus) develop at the application site. While TCDO possesses antimicrobial properties and can reduce bioburden, it is not a substitute for systemic antibiotic therapy in cases of deep or spreading infections, especially those associated with systemic signs of illness such as fever or sepsis. Close monitoring for signs of infection progression or inadequate wound healing is crucial. Use in pregnant or breastfeeding women and pediatric patients is not fully established and should be undertaken with caution, only if clearly indicated and potential benefits outweigh risks, under strict medical supervision.
- Tetrachlorodecaoxide is intended for external topical use only.
- It must not be ingested, injected, or applied to ophthalmic tissues.
- Direct contact with eyes, internal organs, or deep body cavities should be meticulously avoided unless specifically directed by a medical professional for particular indications under controlled settings, due to the potential for severe irritation or damage.
- Patients with known hypersensitivity to tetrachlorodecaoxide, chlorine-releasing compounds, or any components of the formulation should strictly refrain from using this product.
- Discontinue use immediately and seek medical advice if signs of severe local irritation, allergic reaction, such as excessive pain, blistering, or widespread rash, or worsening of the wound condition occur.
- The safety and efficacy in pregnant women, breastfeeding mothers, and pediatric populations have not been extensively established; therefore, it should be used in these groups only if the potential benefits clearly outweigh the potential risks and under strict medical supervision.
- Concomitant use with other strong topical oxidizing or reducing agents should be approached with caution due to potential chemical interactions that could alter efficacy or increase local toxicity.
- Do not use if the solution appears cloudy or discolored.
How it Works (Mechanism of Action)
Tetrachlorodecaoxide (TCDO) is proposed to exert its therapeutic effects primarily through the controlled release of oxygen and the generation of reactive oxygen species (ROS) at the site of application. In hypoxic wound environments, this localized oxygenation is believed to stimulate cellular respiration, enhance fibroblast activity, promote angiogenesis (formation of new blood vessels), and facilitate collagen synthesis, all critical processes for effective wound healing. By improving oxygen supply to the wound bed, TCDO can aid in cellular proliferation and metabolic activity crucial for tissue repair. Beyond its oxygen-releasing capacity, TCDO also demonstrates broad-spectrum antimicrobial activity against a wide range of bacteria, fungi, and viruses. This antimicrobial action is thought to stem from its oxidative properties, which can disrupt microbial cell membranes, inhibit essential enzyme systems, and damage nucleic acids, thereby effectively reducing the bioburden in infected or contaminated wounds. Furthermore, TCDO may modulate inflammatory responses, assist in debridement by breaking down necrotic tissue and fibrin, and neutralize bacterial toxins, creating a more conducive environment for tissue regeneration and epithelialization.
Commercial Brands (Alternatives)
No other brands found for this formula.